Back to top
more

TransMedics Group (TMDX)

(Real Time Quote from BATS)

$86.06 USD

86.06
998,498

+0.56 (0.66%)

Updated Nov 8, 2024 03:44 PM ET

After-Market: $86.01 -0.05 (-0.06%) 4:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now

by Zacks Equity Research

QDEL's strong product portfolio raises optimism about the stock.

Reasons to Retain Chemed Stock in Your Portfolio Now

by Zacks Equity Research

Investors feel optimistic about CHE's strong growth prospects in the VITAS business. Yet, unfavorable macroeconomic conditions are concerning.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Reasons to Retain QIAGEN Stock in Your Portfolio for Now

by Zacks Equity Research

Investors feel optimistic about QGEN's strong growth prospects in the NGS platforms. Yet, an unfavorable currency impact on the company's operations is cornering.

Bruker Stock Gains From Its Latest Acquisition of Dynamic Biosensors

by Zacks Equity Research

BRKR acquires Dynamic Biosensors or DBS. DBS's unique products, along with BRKR's SPR portfolio, should help the latter establish a leading biosensors business.

Labcorp Stock Gains From Biopharma Business Amid FX Woe

by Zacks Equity Research

LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.

New Animal Health Products, Vaccine Sales Support PAHC Stock

by Zacks Equity Research

Phibro Animal Health is focusing on new developments, incremental registrations and volumes of existing vaccine technologies.

Should You Continue to Hold TMO Stock in Your Portfolio?

by Zacks Equity Research

Thermo Fisher advances in its growth strategy, supported by its wave of innovations. However, macroeconomic issues escalate expenses.

Does TransMedics (TMDX) Have the Potential to Rally 26.49% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for TransMedics (TMDX) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here's Why You Should Hold IART Stock in Your Portfolio Now

by Zacks Equity Research

Integra's strong growth in the Tissue Technologies and CSS business segment bolsters investors' confidence in the stock.

Is EXAS Stock a Smart Addition to Your Portfolio Right Now?

by Zacks Equity Research

Exact Sciences is making solid headway in promoting Cologuard as the benchmark for care.

Best Momentum Stocks to Buy for October 3rd

by Zacks Equity Research

TMDX, CCL, and CBU made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 3, 2024.

Is it the Right Time to Hold EW Stock in Your Portfolio Now?

by Zacks Equity Research

Edward Lifesciences' Critical Care divestiture bodes well for its Structural Heart portfolio. Yet, macroeconomic issues raise worry for its operations.

Here's Why You Should Retain BRKR Stock in Your Portfolio Now

by Zacks Equity Research

Bruker's robust growth potential across its Nano segment is encouraging. Yet, unfavorable currency movement is likely to pose a challenge.

New Strong Buy Stocks for October 3rd

by Zacks Equity Research

CCL, TMDX, CBU, RWEOY and ADDYY have been added to the Zacks Rank #1 (Strong Buy) List on October 3, 2024.

HYPR Achieves Positive Swoop System Data for ECMO: Stock to Rise?

by Zacks Equity Research

Hyperfine announces a publication on using the Swoop system for patients on ECMO support. The study showed the safety of using an ultra-low-field portable brain MRI on patients undergoing ECMO.

Here's Why You Should Add BSX Stock to Your Portfolio Now

by Zacks Equity Research

Investors remain optimistic about Boston Scientific due to its geographical expansions and impressive MedSurg market share gain.

Global Expansion, Strategic Innovations Aid Boston Scientific Stock

by Zacks Equity Research

We are impressed with BSX's recent acquisitions that have added numerous products with immense potential.

Reasons to Retain Medtronic Stock in Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about Medtronic due to strength in its Neurosurgery portfolio. Yet, mounting expenses pose a threat to the company's margins.

QIAGEN Launches QIAcuityDx Digital PCR System: Stock to Gain?

by Zacks Equity Research

QGEN expands its digital PCR portfolio with the newly launched QIAcuityDx Digital PCR System. The system will be used for clinical testing in oncology across North America and Europe.

Should You Continue to Hold Bio-Rad Stock in Your Portfolio?

by Zacks Equity Research

BIO strategically expands its ddPCR platform while eyeing global expansion and benefiting from its clinical diagnostics arm.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

BSX Stock Gains From FARAPULSE PFA's PMDA Approval in Japan

by Zacks Equity Research

Boston Scientific achieves PMDA approval for its FARAPULSE PFA System in Japan. The company expects to launch the system in the country in the upcoming weeks.

TransMedics (TMDX) Moves 10.1% Higher: Will This Strength Last?

by Zacks Equity Research

TransMedics (TMDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

HOLX Stock Gains From New Offerings Despite Macro Issues

by Zacks Equity Research

In Breast Health, Hologic expands its product offering from imaging to cover the continuum of breast cancer care, including biopsy and surgery.